Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)
NCT04299893 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 42
Last updated 2025-09-02
Summary
The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy
Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Pain, Neuropathic
- Pain Syndrome
Interventions
- DRUG
-
Ozone
Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
- DRUG
-
Oxygen
Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
Sponsors & Collaborators
-
Servicio Canario de Salud
collaborator OTHER -
Instituto de Salud Carlos III
collaborator OTHER_GOV -
Red de Investigación en Servicios de Salud en Enfermedades Crónicas
collaborator OTHER -
Fundación DISA, Spain
collaborator UNKNOWN -
Fundación Española del Dolor (FED)
collaborator UNKNOWN -
Bernardino Clavo, MD, PhD
lead OTHER
Principal Investigators
-
Bernardino Clavo, MD, PhD · Dr. Negrín University Hospital, Las Palmas, Spain
-
Pedro G Serrano-Aguilar, MD, PhD · Servicio de Evaluación. Servicio Canario de Salud. Spain
-
Delvys Rodríguez-Abreu, MD · Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas, Spain
-
Gustavo M Callico, Prof, PhD · Institute for Applied Microelectronics, University of Las Palmas de G. C., Spain
-
Francisco Rodríguez-Esparragón, BSc, PhD · Dr. Negrín University Hospital, Las Palmas, Spain
-
Bernardino Clavo, MD, PhD · Dr. Negrín University Hospital, Las Palmas, Spain
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-30
- Primary Completion
- 2027-09-30
- Completion
- 2027-12-31
Countries
- Spain
Study Locations
More Related Trials
-
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
NCT07072468 ·Status: RECRUITING ·Phase: PHASE2
-
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
NCT05388058 ·Status: COMPLETED ·Phase: PHASE2
-
Neuropathic Pain Caused by Radiation Therapy
NCT00798083 ·Status: COMPLETED ·Phase: PHASE3
-
Exploration of Neuropathic Pain Induced by Oxaliplatin Electrophysiological Approach
NCT02827916 ·Status: COMPLETED ·Phase: NA
-
D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain
NCT00301080 ·Status: TERMINATED ·Phase: PHASE3
-
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
NCT06389721 ·Status: RECRUITING
-
Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel
NCT02297412 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study.
NCT02137954 ·Status: UNKNOWN ·Phase: PHASE3
-
Scrambler Therapy in Treating Pain and Peripheral Neuropathy in Patients Previously Treated With Chemotherapy
NCT01347723 ·Status: COMPLETED
-
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
NCT06848348 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy
NCT01006408 ·Status: COMPLETED ·Phase: NA
-
Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy
NCT02000908 ·Status: COMPLETED ·Phase: NA
-
Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy
NCT02492360 ·Status: WITHDRAWN
-
Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
NCT00996983 ·Status: UNKNOWN ·Phase: PHASE2
-
NPC-06 to Acute Pain in Herpes Zoster
NCT04139330 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain
NCT03317613 ·Status: COMPLETED ·Phase: PHASE2
-
Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study
NCT06121232 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
NCT01201317 ·Status: COMPLETED ·Phase: PHASE2
-
Peripheral Blood Biomarkers Associated With CIPN
NCT02661399 ·Status: COMPLETED
-
Topical Menthol +/- Mannitol for Painful Diabetic Peripheral Neuropathy
NCT02728687 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Lidocaine Patch in Treating Cancer Patients With Neuropathic Pain After Surgery
NCT00058357 ·Status: COMPLETED ·Phase: PHASE3
-
Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
NCT00068445 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Peri-neural Platelet Rich Plasma Injection in Treatment of Chemotherapy Induced Peripheral Neuropathy
NCT05348408 ·Status: COMPLETED ·Phase: PHASE2
-
SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.
NCT06614322 ·Status: RECRUITING ·Phase: PHASE2
-
Compounded Pain Creams and Patient Perception
NCT02024802 ·Status: WITHDRAWN